BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

7:03 PM
Sep 26, 2008
 |  BC Extra  |  Clinical News

Novo Nordisk reports liraglutide extension data

Novo Nordisk (CSE:NVO; NYSE:NVO) released data from an extension of the Phase IIIb LEAD-6 trial that showed patients who switched from twice-daily Byetta exenatide to once-daily liraglutide had a statistically significant 0.3%...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >